Laboratorios Farmaceuticos Rovi, SA Financials

Market Capitalization €3.08 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	18.92
Forward PE	22.20
Price to Sales TTM	€3.85
Price to Book MRQ	€5.85
Enterprise to Revenue	3.94
Enterprise to EBITDA	13.47

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	20.64%
Operating Margin	38.28%
Return on Assets TTM	15.55%
Return on Equity TTM	29.65%

Income Statement

Revenue TTM	€799,248,000
Revenue per Share TTM	€14.97
Quarterly Revenue Growth	9.90%
Gross Profit TTM	€488,921,984
EBITDA	€240,774,000
Net Income to Common TTM	€165,000,000
Diluted EPS TTM	€3.18
Quarterly Earnings Growth YoY	32.50%

Balance Sheet

Total Cash MRQ	€17,554,000
Total Cash per Share MRQ	€0.34
Total Debt MRQ	€
Total Debt to Equity MRQ	22.98
Current Ratio MRQ	2.50
Book Value per Share MRQ	€10.28

Cash Flow

Operating Cash Flow TTM	€126,182,000
Levered Free Cash Flow TTM	€48,538,876

ROVI Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	51,153,000
Float Shares	18,606,141
Avg 10 Volume	86,972
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	63.25%
% Held by Institutions	18.89%

Stock Price Summary

Beta	0.48
Fifty Two Week Low	€57.20
Fifty Two Week High	€94.80
Fifty Two Week Change	2.55%
Day 50 MA	€63.71
Day 200 MA	€76.79

Dividends and Splits

Forward Annual Dividend Rate	€4.41
Forward Annual Dividend Yield	7.04%
Trailing Annual Dividend Rate	€1.10
Trailing Annual Dividend Yield	1.76%
Payout Ratio	34.74%
Dividend Date
Ex Dividend Date	2024-07-08
Last Split Factor
Last Split Date